CompletedInterventionalPhase 3Updated Nov 11, 2013
A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression | NCT00363337 | Trialant
CompletedInterventionalPhase 4Updated Jun 22, 2011
A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression
ClinicalTrials.gov ID
NCT00363337
Lead Sponsor
Lindner Center of HOPEOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
31Actual
Last Update Posted
Jun 22, 2011Estimated
Start Date
Aug 2006
Primary Completion Date
Mar 2009Actual
Completion Date
Mar 2009Actual
Brief Summary
The specific aim of this study is to obtain preliminary evidence of the acute effectiveness and tolerability of aripiprazole in the treatment of bipolar depression.
Bipolar Depression
aripiprazole
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
subjects must have bipolar I, II or NOS disorder as defined by DSM-IV-TR; must have clinical significant depressive symptoms and have failed one or more mood stabilizer trials; may or may not be receiving antimanic or mood stabilizing medications; subjects or legally authorized representative must sign the Informed Consent document after the nature of the trial has been fully explained; if female, subjects must be postmenopausal, surgically incapable of childbearing or practicing medically acceptable effective method(s) of contraception.
Exclusion Criteria:
subjects who do not have bipolar disorder by DSM-IV criteria; subjects with current DSM-IV Axis I diagnosis of delirium, dementia, amnesia or other cognitive disorders or a psychotic disorder; subjects with serious general medical illness; subjects who are allergic to or have demonstrated hypersensitivity to aripiprazole; women who are pregnant or nursing; subjects who have received an experimental drug or used an experimental device within 30 days; subjects who have a history of neurologic malignant syndrome.